Today: 21 May 2026
ConocoPhillips stock (COP) jumps 3% as OPEC+ meeting and Venezuela headlines loom
4 January 2026
2 mins read

ConocoPhillips stock (COP) jumps 3% as OPEC+ meeting and Venezuela headlines loom

NEW YORK, January 4, 2026, 03:44 ET — Market closed

  • ConocoPhillips ended Friday up 3.3% at $96.70, outpacing Exxon Mobil and Chevron.
  • Traders are eyeing an OPEC+ policy decision and fast-moving Venezuela developments ahead of Monday’s open.
  • ConocoPhillips is scheduled to report quarterly results and discuss 2026 guidance on Feb. 5.

ConocoPhillips shares rose 3.3% to $96.70 at Friday’s close, outperforming larger rivals Exxon Mobil and Chevron and finishing with higher-than-average trading volume. The stock remains about 9% below its 52-week high, according to market data.

The outperformance matters because oil producers’ cash flow expectations still pivot on crude prices, which can swing quickly on supply headlines. For ConocoPhillips, a pure-play upstream producer, shifts in the oil market typically flow straight into earnings power and shareholder-return capacity.

Investors are also tracking OPEC+, the Organization of the Petroleum Exporting Countries plus allies including Russia, with the group expected to keep output policy steady at a meeting on Sunday. The coalition’s stance has become a key driver for energy equities after a sharp slide in oil prices last year revived fears of an oversupplied market.

Venezuela has added a fresh layer of uncertainty. ConocoPhillips is monitoring developments there and said it would be premature to speculate about future business activity or investments, a company spokesperson told Reuters, as traders weigh what any change in the country’s oil outlook could mean for heavy-crude supply.

U.S. President Donald Trump said on Saturday that major U.S. oil companies were prepared to invest billions in Venezuela to restore crude output following the capture and removal of Nicolás Maduro by U.S. forces. “The company that probably will be very interested in going back is Conoco,” Francisco Monaldi, director of the Latin America Energy Program at Rice University’s Baker Institute, said, pointing to money Conoco is owed from prior disputes; he added that Conoco is owed more than $10 billion. Reuters

Oil prices have been choppy into the new year. Brent crude traded around $61 a barrel and U.S. West Texas Intermediate (WTI) — the U.S. benchmark — near $58 on Friday, after both contracts notched their biggest annual losses since 2020 in 2025, Reuters reported. Analysts cited by Reuters expected Brent to hold in a roughly $60–$65 range and WTI in a $55–$65 band in early 2026, barring a major supply shock.

Friday’s rally left ConocoPhillips ahead of Exxon and Chevron on the day, a reminder that single-session moves in the group often reflect beta to crude rather than company-specific fundamentals. Still, traders have treated large-cap E&Ps as liquid vehicles for expressing views on supply risks.

Before Monday’s session, investors will be watching how oil futures react to any signals from the OPEC+ meeting, which can reset near-term price expectations at the open. A firmer tape in crude typically supports upstream shares, while renewed pressure can quickly drag the group.

Venezuela-related headlines are also likely to remain a volatility driver, but investors will be looking for practical details — stability, contract terms and the status of U.S. restrictions — rather than political statements. Heavy crude, a thicker grade that many U.S. Gulf Coast refineries are designed to process, is the key link between Venezuela’s output prospects and U.S. energy markets.

ConocoPhillips’ next company-specific catalyst is its quarterly update. The company plans to release fourth-quarter results before the market opens on Feb. 5 and hold a conference call at noon ET to discuss financial results and 2026 guidance, it said.

Stock Market Today

  • SpaceX Set to Go Public: Key Details and Market Impact
    May 20, 2026, 8:02 PM EDT. SpaceX, founded by Elon Musk, is poised to go public, joining hundreds of companies that raised $70 billion in U.S. equity markets last year. Going public means the company will offer shares for sale on stock exchanges, allowing investors to buy ownership stakes. This move could unlock significant capital for SpaceX's ambitious space ventures, while providing early investors a chance to realize gains. The offering is closely watched amid a strong appetite for tech and aerospace stocks, reflecting broader market interest in innovation-driven firms.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Previous Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds
Next Story

Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds

Go toTop